Roth Affirms Ligand Pharma (LGND) at 'Buy'; Captisol, Promacta Lead Strong Q1 Results

May 7, 2014 11:49 AM

Roth Capital is commenting on Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) following the company's Q1 report. Roth has Ligand at ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found